Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Autism Res. 2020 Oct 27;14(1):29–45. doi: 10.1002/aur.2418

Figure 5.

Figure 5.

IGF-2, but not M6P, attenuates audiogenic seizures in Ube3am−/p+ mice. S.c. injection of IGF-2, M6P, or respective vehicles was administered 20 min before audiogenic seizure induction. (A) Percentage of Ube3am−/p+ mice injected with vehicle or IGF-2 exhibiting wild running and/or tonic–clonic seizures following an audiogenic stimulus. Chi-square test, *P < 0.05. (B) Percent of Ube3am−/p+ mice injected with vehicle or M6P exhibiting wild running and/or tonic–clonic seizures following an audiogenic stimulus. (C) Severity score of audiogenic seizures; 0 = no seizure response; 1 = wild running; 2 = tonic–clonic seizure. Kruskal–Wallis test with Dunn’s multiple comparisons, *P < 0.05. (D) Graph summarizing the percentage of wild running, tonic–clonic or protection from both wild running and tonic–clonic seizure in Ube3am−/p+ mice with vehicle, IGF-2, or M6P treatment; n = 8–11 per group.